SG/CALL/MODERNA/140/0.1/20.09.24 | Market Closed - Euronext Paris 10:00:00 28/05/2024 pm IST | ||
| 2.285 EUR | -33.19% |
|
| Current month | +258.27% | ||
| 1 month | +333.04% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 2.285 | -33.19% |
| 27/24/27 | 3.42 | -5.79% |
| 24/24/24 | 3.63 | +9.34% |
| 23/24/23 | 3.32 | +15.28% |
| 22/24/22 | 2.88 | +69.91% |
Real-time Euronext Paris
Last update May 28, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| N819S | |
| ISIN | DE000SU6MG56 |
| Date issued | 04/01/2024 |
| Strike | 140 $ |
| Maturity | 20/09/2024 (115 Days) |
| Parity | 10 : 1 |
| Emission price | 1.46 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.7 € |
|---|---|
| Lowest since issue | 0.305 € |
| Spread | 0.01 € |
| Spread % | 0.42% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
166.6
USD
Average target price
138.5
USD
Spread / Average Target
-16.86%
- Stock Market
- Warrants
- N819S Warrant
